ProQR

Historical price data

ProQR Therapeutics is a mission-driven, clinical-stage biotechnology company dedicated to developing life-changing RNA therapies for severe rare and common genetic diseases. Its core achievement is the invention of the Axiomer® RNA editing platform, a next-generation technology enabling precise single-nucleotide correction, which has attracted a major multi-target collaboration with Eli Lilly. The company's strategy is to advance its internal pipeline in ophthalmology while leveraging partnerships to expand the application of Axiomer into new therapeutic areas like the liver and central nervous system, aiming to establish clinical proof-of-concept and build a sustainable, platform-based biotech.

Proprietary Axiomer® RNA editing platform that uses engineered oligonucleotides (EONs) to recruit endogenous ADAR enzymes for precise single-nucleotide (A-to-I) correction of RNA, addressing the root cause of genetic diseases.

ProQR competes in the emerging RNA editing field against companies like Wave Life Sciences and Ascidian, and more broadly against CRISPR-based gene editing and traditional oligonucleotide therapies. Its key differentiators are the use of endogenous ADAR enzymes and a first-mover clinical candidate, but the space is rapidly evolving and highly competitive.